BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38533515)

  • 1. TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes.
    Trivedi P; Jhala G; De George DJ; Chiu C; Selck C; Ge T; Catterall T; Elkerbout L; Boon L; Joller N; Kay TW; Thomas HE; Krishnamurthy B
    Front Immunol; 2024; 15():1370907. PubMed ID: 38533515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
    Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
    Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
    Josefsson SE; Huse K; Kolstad A; Beiske K; Pende D; Steen CB; Inderberg EM; Lingjærde OC; Østenstad B; Smeland EB; Levy R; Irish JM; Myklebust JH
    Clin Cancer Res; 2018 Feb; 24(4):870-881. PubMed ID: 29217528
    [No Abstract]   [Full Text] [Related]  

  • 5. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
    Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8
    Banta KL; Xu X; Chitre AS; Au-Yeung A; Takahashi C; O'Gorman WE; Wu TD; Mittman S; Cubas R; Comps-Agrar L; Fulzele A; Bennett EJ; Grogan JL; Hui E; Chiang EY; Mellman I
    Immunity; 2022 Mar; 55(3):512-526.e9. PubMed ID: 35263569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the immune checkpoint molecules CD226 and TIGIT in preeclampsia patients.
    Li C; Liu H; Duan Z
    BMC Immunol; 2024 Feb; 25(1):12. PubMed ID: 38326745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis.
    Deng C; Li W; Fei Y; Wang L; Chen Y; Zeng X; Zhang F; Li Y
    Front Immunol; 2020; 11():1619. PubMed ID: 32793241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer.
    Martinez M; Kim S; St Jean N; O'Brien S; Lian L; Sun J; Verona RI; Moon E
    Oncoimmunology; 2021 Jan; 10(1):1873607. PubMed ID: 33537176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling.
    Huang M; Yu X; Wang Q; Jiang Z; Li X; Chen W; Song C
    Cell Commun Signal; 2024 Jan; 22(1):35. PubMed ID: 38216949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoreactive effector/memory CD4+ and CD8+ T cells infiltrating grafted and endogenous islets in diabetic NOD mice exhibit similar T cell receptor usage.
    Diz R; Garland A; Vincent BG; Johnson MC; Spidale N; Wang B; Tisch R
    PLoS One; 2012; 7(12):e52054. PubMed ID: 23251685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD155T/TIGIT Signaling Regulates CD8
    He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
    Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor.
    Zhao J; Dong J; Deng C; Zhang Q; Sun S; Li H; Bai Y; Deng H
    Oncoimmunology; 2023; 12(1):2265703. PubMed ID: 37808405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic expression of B7 co-stimulatory molecules in the non-obese diabetic mouse.
    Stephens LA; Kay TW
    Int Immunol; 1995 Dec; 7(12):1885-95. PubMed ID: 8746558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-Cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection.
    El Khatib MM; Sakuma T; Tonne JM; Mohamed MS; Holditch SJ; Lu B; Kudva YC; Ikeda Y
    Gene Ther; 2015 May; 22(5):430-8. PubMed ID: 25786871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking TIGIT/CD155 signalling reverses CD8
    Liu L; Wang A; Liu X; Han S; Sun Y; Zhang J; Guo L; Zhang Y
    J Transl Med; 2022 Jun; 20(1):280. PubMed ID: 35729552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8
    Wang M; Bu J; Zhou M; Sido J; Lin Y; Liu G; Lin Q; Xu X; Leavenworth JW; Shen E
    Clin Immunol; 2018 May; 190():64-73. PubMed ID: 28893624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade.
    Yoo KJ; Johannes K; González LE; Patel A; Shuptrine CW; Opheim Z; Lenz K; Campbell K; Nguyen TA; Miriyala J; Smith C; McGuire A; Tsai YH; Rangwala F; de Silva S; Schreiber TH; Fromm G
    J Immunol; 2022 Aug; 209(3):510-525. PubMed ID: 35817517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade.
    Pearce H; Croft W; Nicol SM; Margielewska-Davies S; Powell R; Cornall R; Davis SJ; Marcon F; Pugh MR; Fennell É; Powell-Brett S; Mahon BS; Brown RM; Middleton G; Roberts K; Moss P
    Cancer Immunol Res; 2023 Apr; 11(4):435-449. PubMed ID: 36689623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in adhesion markers, activation markers, and TcR in islet infiltrating vs. peripheral lymphocytes in the NOD mouse.
    Goldrath AW; Barber L; Chen KE; Alters SE
    J Autoimmun; 1995 Apr; 8(2):209-20. PubMed ID: 7612149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.